A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Trial Profile

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Idasanutlin (Primary) ; Idasanutlin (Primary)
  • Indications Cancer
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 04 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top